183 related articles for article (PubMed ID: 33385970)
1. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody.
Menezes B; Khera E; Calopiz M; Smith MD; Ganno ML; Cilliers C; Abu-Yousif AO; Linderman JJ; Thurber GM
AAPS J; 2022 Oct; 24(6):107. PubMed ID: 36207468
[TBL] [Abstract][Full Text] [Related]
3. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
4. Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates.
Khera E; Dong S; Huang H; de Bever L; van Delft FL; Thurber GM
Mol Cancer Ther; 2022 Feb; 21(2):310-321. PubMed ID: 34911819
[TBL] [Abstract][Full Text] [Related]
5. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
Burton JK; Bottino D; Secomb TW
AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
7. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
8. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
10. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
11. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
[TBL] [Abstract][Full Text] [Related]
12. Increased Tumor Penetration of Single-Domain Antibody-Drug Conjugates Improves
Nessler I; Khera E; Vance S; Kopp A; Qiu Q; Keating TA; Abu-Yousif AO; Sandal T; Legg J; Thompson L; Goodwin N; Thurber GM
Cancer Res; 2020 Mar; 80(6):1268-1278. PubMed ID: 31941698
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Catabolism of [
Bolleddula J; Shah A; Shadid M; Kamali A; Smith MD; Chowdhury SK
Drug Metab Dispos; 2020 Nov; 48(11):1239-1245. PubMed ID: 32843329
[TBL] [Abstract][Full Text] [Related]
14. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release.
Kopp A; Hofsess S; Cardillo TM; Govindan SV; Donnell J; Thurber GM
Mol Cancer Ther; 2023 Jan; 22(1):102-111. PubMed ID: 36190986
[TBL] [Abstract][Full Text] [Related]
16. Modeling to capture bystander-killing effect by released payload in target positive tumor cells.
Byun JH; Jung IH
BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates.
Li F; Ulrich M; Jonas M; Stone IJ; Linares G; Zhang X; Westendorf L; Benjamin DR; Law CL
Mol Cancer Ther; 2017 Jul; 16(7):1347-1354. PubMed ID: 28341790
[TBL] [Abstract][Full Text] [Related]
18. Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.
Nicolaou KC; Rigol S; Pitsinos EN; Das D; Lu Y; Rout S; Schammel AW; Holte D; Lin B; Gu C; Sarvaiya H; Trinidad J; Barbour N; Valdiosera AM; Sandoval J; Lee C; Aujay M; Fernando H; Dhar A; Karsunky H; Taylor N; Pysz M; Gavrilyuk J
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34155147
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived Xenografts.
Abu-Yousif AO; Cvet D; Gallery M; Bannerman BM; Ganno ML; Smith MD; Lai KC; Keating TA; Stringer B; Kamali A; Eng K; Koseoglu S; Zhu A; Xia CQ; Landen MS; Borland M; Robertson R; Bolleddula J; Qian MG; Fretland J; Veiby OP
Mol Cancer Ther; 2020 Oct; 19(10):2079-2088. PubMed ID: 32788205
[TBL] [Abstract][Full Text] [Related]
20. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
Bai C; Reid EE; Wilhelm A; Shizuka M; Maloney EK; Laleau R; Harvey L; Archer KE; Vitharana D; Adams S; Kovtun Y; Miller ML; Chari R; Keating TA; Yoder NC
Bioconjug Chem; 2020 Jan; 31(1):93-103. PubMed ID: 31747250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
